Company intelligence / Profile preview

Tamid Bio

Ownership: Private
Development stage: Other

Overview

Tamid Bio develops AAV-based gene therapies for rare/orphan diseases. Its lead program, Tamid‑001, targets the ocular symptoms of MPS I and has shown proof-of-principle efficacy in a canine model. Two additional preclinical programs target dysferlinopathies and corneal transplant rejection. All programs are preclinical as of the latest public update.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: Gene therapy (Adeno-associated virus gene therapy)Biologic
Industry: Biotech

Drug pipeline

1 asset

Tamid-001

Preclinical

Partnerships

University of North Carolina at Chapel Hill – exclusive licensing for three AAV-based preclinical assets developed by Dr. Matthew Hirsch’s lab at UNC Gene Therapy Center

Beyond the preview

Go deeper on Tamid Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tamid Bio.

Explore the full profile